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Abstract: Sickle cell disease and Sarcoidosis are conditions that are more common in the African American population. In this report we
share an unfortunate patient who had hepatic sarcoidosis but could not receive steroids since that precipitated acute liver failure. We have
discussed potential therapy options but we need more options that improve mortality.
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Introduction

Sarcoidosis and hemoglobinopathies are 2 disorders commonly
affecting the black population. Sarcoidosis occurs at a rate of
about 30 to 40 per 100 000 in the general population, and
approximately 0.15% of African Americans are homozygous
and hence have sickle cell disease (SCD).1 We are reporting
a patient with SCD who survived childhood to later develop
sarcoidosis which caused liver impairment. When oral steroids
were used to manage hepatic sarcoidosis, it precipitated sickling. We could find no previous report in the published literature regarding guidance on management of such a patient. We
realize this report raises more questions than answers but
strongly believe these data need to be collected to formulate
optimal care in patients with sickle cell hepatopathy or hepatic
sarcoidosis or when they occur together.

Case Report

A 34-year-old African American man with known SCD on
chronic exchange transfusions (secondary to stroke at the age
of 6) was diagnosed with pulmonary and ocular sarcoid. He
also had a history of atrial fibrillation, post defibrillator placement for cardiomyopathy, and history of sudden cardiac deaths
in the family and was on rivaroxaban.
He was initially started on low-dose prednisone and methotrexate for sarcoidosis, which precipitated his first sickle cell
crisis in more than a decade. He presented with pain and anemia, with his hemoglobin falling from a baseline of 8 to 6
g/dL requiring blood transfusions. His liver panel showed
aspartate aminotransferase (AST) of 213 U/L, alanine aminotransferase (ALT) of 68 U/L, alkaline phosphatase of 373
U/L, total bilirubin of 26.3 mg/dL, conjugated bilirubin of
22.7 mg/dL, and international normalized ratio (INR) of 1.3.
Liver biopsy showed exuberant granuloma with sinusoid sickling. Rivaroxaban was changed to warfarin after discussion
with the family, mainly for the convenience of monitoring and
reversing coagulopathy if needed.
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He was admitted within a year of initial diagnosis of sarcoidosis for progressively worsening limb edema and ascites.
Furosemide and spironolactone had minimal response. He had
a large-volume paracentesis performed, which revealed no evidence of spontaneous bacterial peritonitis. The appearance of
Ascitic fluid was orange in color with total nucleated cells of
26433/mm3 among which total nucleated cells were 60/mm3 L
with 81% polymorphs. He was also found to be encephalopathic, and lactulose was initiated. Other causes of acute liver
failure, including paracetamol ingestion, were ruled out because
the levels were undetectable. Also, the patient was never found
to have adverse effects of incompatible blood transfusion.
Hepatitis C virus was negative and serum albumin was 2.9
mg/dL, with partial thromboplastin time elevated to more than
150 during his whole hospital course. D-dimer was moderately
increased. Hepatology continued to advocate for azathioprine.
Warfarin was held secondary to coagulopathy. He developed a
nose bleed for which he was treated with fresh frozen plasma
and vitamin K with some resolution of symptoms. His Model
for End-Stage Liver Disease was calculated at 35, but because
he did not have cirrhosis these scores were inaccurate. He was
transferred to the intensive care unit after he started bleeding
from the site of his paracentesis and had to have purse string
sutures placed. The patient continued to be in acute liver failure, and despite optimal supportive therapy, he developed an
intracranial bleed with adverse outcome. During this time
period, his INR reached up to 7.5 which was corrected down to
3.1. International normalized ratio has been used here even
after cessation of warfarin because it is a test for synthetic function too. Abdominal ultrasound during this period showed
massive hemoperitoneum most prominent in the left lower
quadrant. His AST peaked at 7922 U/L, ALT at 1389 U/L,
alkaline phosphatase at 233 U/L, and total bilirubin at
47.7 mg/dL, with direct bilirubin greater than 30 mg/dL
during this hospital course.
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Laboratory values.
Laboratory values

At the time of admission

Peaked values

AST

213 U/L

7922 U/L

ALT

68 U/L

1398 U/L

Alkaline phosphatase

373 U/L

233 U/L

Total bilirubin

26.3 mg/dL

47.7 mg/dL

Direct bilirubin

22.7 mg/dL

30 mg/dL

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Discussion

Sarcoidosis and hemoglobinopathies are 2 disorders commonly affecting the African American population. The prevalence of sarcoidosis is largely dependent on race and ethnicity.
The association of sarcoidosis and SCD has been reported in
few cases.2
Although sarcoid granulomas are present in the liver on
histopathology in patients with pulmonary disease, these
granulomas causing an abnormal liver panel are not very
usual.3,4 Liver panel abnormality reported in the form of elevated alkaline phosphatase (most common) in 20% to 40% of
patients with sarcoid granulomas in the liver hardly ever causes
symptoms in the form of hepatosplenomegaly (15%-40%) or
lymphadenopathy (15%).5
Therefore, hepatic sarcoid can be classified into 4 groups.
Group 1 patients have asymptomatic or incidental granulomas
randomly found during liver biopsy or to substantiate the diagnosis of sarcoidosis. Group 2 patients have hepatomegaly or
splenomegaly with evidence of mild hepatic derangement.
Group 3 are patients with hepatocellular disease with or without portal hypertension. Group 4 are patients with portal
hypertension as the major manifestation. Advanced signs of
liver failure like in our patient include ascites, jaundice, hepatic
encephalopathy, and bleeding diathesis.6
Life-threatening complications of sarcoidosis are rare. The
mortality rates were estimated to be 4.32/1 000 000 between
1988 and 2007. Respiratory and cardiac complications are the
most common causes of death. The leading cause of death in
such patients is a result of pulmonary fibrosis followed by cardiac failure. Acute fulminant hepatic failure as a complication
of sarcoidosis is rare, with an incidence of less than 5% in
patients with hepatic sarcoidosis.
Although glucocorticoids are the most commonly used
therapeutic agents for sarcoidosis, patients with SCD incur the
risk of developing severe sickle cell–related clinical manifestation during treatment with steroids.7 Delmonte et al8 reported
a patient with sarcoidosis and SCD successfully treated with
low-dose prednisone and methotrexate.
There are no defined protocols or recommendations for
indications of initiation of treatment, drug choice, and dosage
or duration of therapy in patients with hepatic sarcoidosis.
Although there are no randomized controlled trials, steroids

have been shown to improve clinical symptoms, liver enzymes,
and even reduce hepatomegaly. Azathioprine and infliximab
have also been used for maintenance therapy. However, the
effect of these agents on the natural history of hepatic sarcoidosis is unknown.9
Ahn et al. reported cases of sickle cell hepatopathy and
classified the patients into 2 major groups. They defined
sickle cell hepatopathy as serum bilirubin greater than 13
mg/dL not explained by acute hemolysis, viral hepatitis,
extrahepatic obstruction, or hepatic sequestration. The
patients in the first group had milder disease with no manifestation of severe hepatic damage and a mean bilirubin of
27.6 mg/dL. The patients in the second group had more
severe hepatic dysfunction, with a mean bilirubin of 76.8
mg/dL, accompanied by altered mental status and/or prolonged coagulation times. Mortality in the first group was
4% and in the second group was 64%.10 They found exchange
transfusion to be the only effective treatment in early cases of
sickle cell hepatopathy.
Liver transplantation used as a management strategy for
sickle cell hepatopathy has not been widely studied. PubMed
search identified 10 adults and 5 children with SCD who
underwent orthotopic liver transplantation. Of the 10 adults, 4
died in the immediate postoperative period and 5 of the
remaining 6 eventually died due to sickle cell–related allograft
complications; in the pediatric group, 3 of the 5 patients survived postoperatively.11–14 In successful adult patient with
orthotopic liver transplant, it was noted that aggressive preoperative and postoperative red cell transfusions (to a goal hemoglobin of greater than 10 g/dL—requiring 2 U every 4 weeks)
prevented sickling in the graft liver. But this also placed the
patient at risk of iron overload.
This patient is probably the first reported case of fatal SCD
combined with hepatic sarcoidosis. A PubMed search did not
reveal a prior reported case of the same. His sarcoidosis could
not be treated with steroid, which is the first-line agent because
it flared his sickle cell crisis. This led to stopping his steroids
and other immunomodulators, but a combination of sickling
in liver sinusoids and active sarcoid granulomas in his liver
resulted in acute liver failure. We wonder whether liver transplantation would be the answer to this dilemma, but it would
have probably resulted in recurrence of the disease processes in
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the transplanted liver if the patient had survived the posttransplantation period.
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